Active Studies

Excell Research may be seeking participants for an upcoming clinical research study for an area or disease that is relevant to you or someone you know.

Studies Available to Volunteers

Depression Studies

1. Sponsor: Alto Neuroscience

Protocol Number: ALTO-100-201

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder

Inclusion Criteria:

  • Ages: 18-64
  • Have a diagnosis of moderate to severe major depressive disorder (MDD)
  • Can stay on an antidepressant medication if taking one.
  • Must not be pregnant or breastfeeding at time of enrollment or throughout study
  • Reimbursement for time and travel up to $700

Exclusion Criteria:

  • Evidence of unstable medical condition
  • Diagnosed bipolar disorder, psychotic disorder, or dementia
  • Current moderate or severe substance use disorder
  • Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device.

2. Sponsor: DeNovo Biopharma LLC

Protocol Number: DB104-01

A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression

Inclusion Criteria:

  • Ages: 18-64
  • Have a diagnosis of moderate to severe major depressive disorder (MDD)
  • Has tried 2 or more Antidepressants of a different class in the past 5 years.
  • Must not be pregnant or breastfeeding at time of enrollment or throughout study
  • Reimbursement for time and travel up to $900
Generalized Anxiety Study
  1. Sponsor: Sunovion Pharmaceuticals

Protocol Number: SEP361-226

A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder

Inclusion criteria:

    • Age 18-65
    • Moderate to Severe symptoms of Generalized Anxiety
    • No Previous diagnosis required
    • Reimbursement for time and travel up to $1,500
Schizophrenia Studies
  1. Sponsor: Neurocrine Biosciences

Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia

Inclusion criteria:

    • Age 18-75
    • Currently being treated with an anti-psychotic medication.
    • Reimbursement for time and travel up to $1,200
OCD Study
  1. Sponsor: Biohaven Pharmaceuticals

Protocol Number: BHV4157-302

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Inclusion criteria:

    • Age 18-65
    • Moderate to severe symptoms of OCD.
    • Currently taking an SSRI medication for 8 weeks prior to the study.
    • Reimbursement for time and travel up to $700.
Adolescent Migraine Studies
  1. Sponsor: Abbvie Pharmaceuticals

Protocol Number: 3110-305-002 & M21-201

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

Inclusion criteria:

    • Age 11-17 (Excell Research Age Range)
    • Have up to 4 Migraines days a month.
    • No previous medications required.
    • Reimbursement for time and travel up to $300.

Sponsor: Abbvie Pharmaceuticals

Alzheimer's Disease Study
  1. Sponsor: Otsuka Pharmaceuticals

Protocol Number: 20-AVP-786-306

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type

Inclusion criteria:

    • Age 50-90
    • Previous diagnosis of Alzheimer’s Disease and a legal caregiver required.
    • Reimbursement for time and travel up to $1,000 for patient and caregiver.

Research volunteers play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.

Patients who participate in Excell Research’s clinical trials have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of medical conditions.

We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.

Financial Compensation maybe available to those who qualify and complete visits for our Clinical Trials.

Excell Research Clinical TrialsWhy Participate?

For those interested in becoming a volunteer, Excell Research has a variety of studies that are testing new or investigational medications at no cost to volunteers! Learn more about how new treatments may help with your symptoms.

https://excellresearch.com/wp-content/uploads/2023/08/qtq80-VpnKce.jpeg

How You Can Contribute

Clinical trials create a new opportunity for patients to receive alternative or more varied treatment, and to get up close and personal treatment from healthcare professionals. Often, clinical trials provide financially viable treatment options that may not have otherwise been available. By participating in a clinical trial, you would be aiding health care officials in their efforts to advance medical knowledge and to find new and better treatment options for patients.

 

New Treatments For Longer and Better-Quality Lives

The primary goal of all clinical trials is to determine that the new treatment is both effective and safe for patients. A clinical trial may seek a cure or new methods to ease the lives of patients with chronic illnesses. Participating in a clinical trial allows you to receive the most cutting-edge treatment or procedures in the medical field, and to assist in helping other patients live longer and better-quality lives.

 

Patient Safety

To ensure the safety of patients during clinical trials, Excell Research follows guidelines set by organizations such as the U.S. Food & Drug Administration and the Global International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices (ICH GCP).

According to requirements of the Medical Board of California, medical providers at Excell Research are providing information about the Open Payments Database.  The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov.  This database was created so that patients can be informed of any possible influence pharmaceutical companies may have on their physician.  As a dedicated research facility, the entirety of Excell Research’s income is from pharmaceutical companies; however, medical providers are paid for their work by Excell Research and not directly by any pharmaceutical company.

Excell Research Clinical TrialsSign-Up For Monthly Study Updates

https://excellresearch.com/wp-content/uploads/2023/08/qtq80-lHlUrD.jpeg